Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012

Désirée Larenas-Linnemann1, Michael Blaiss, Hugo P Van Bever

  • 1Hospital Médica Sur, Mexico City, Mexico. Marlar1@prodigy.net.mx

Insights

Sublingual immunotherapy (SLIT) shows growing evidence for treating children's allergies. This review found robust efficacy for grass pollen SLIT and good evidence for house dust mite SLIT in asthma, with no anaphylaxis reported.

Area of Science:

  • Pediatric Allergy and Immunology
  • Immunotherapy Research
  • Clinical Evidence Synthesis

Background:

  • Sublingual immunotherapy (SLIT) is an alternative to subcutaneous immunotherapy for allergic diseases.
  • Evidence for SLIT's efficacy in pediatric populations requires ongoing evaluation.
  • Assessing the quality and scope of recent SLIT research is crucial for clinical practice.

Purpose of the Study:

  • To systematically analyze the latest scientific evidence on the clinical efficacy of SLIT in children.
  • To evaluate SLIT's effectiveness for various allergic conditions, including respiratory and food allergies.
  • To assess the quality of evidence and identify emerging trends in pediatric SLIT research.

Main Methods:

  • Comprehensive literature search of PubMed, Embase, and other databases (2009-2012).
  • Inclusion of original articles on clinical trials of SLIT in patients under 18 years.
  • Quality assessment using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

Main Results:

  • 29 trials met inclusion criteria, showing robust evidence for grass pollen SLIT in allergic rhinitis.
  • High-quality evidence supports house dust mite (HDM) SLIT for medication reduction in pediatric asthma.
  • Moderate evidence suggests efficacy for dual grass pollen-HDM SLIT; food SLIT shows less promise than oral immunotherapy.

Conclusions:

  • The body of evidence supporting the efficacy of SLIT in children with respiratory and food allergies is expanding.
  • SLIT demonstrates potential for managing allergic rhinitis and asthma in pediatric patients.
  • Further research is needed to solidify evidence for specific allergens and food allergies.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...